Clinical Trial - Trial ChiCTR2200061301
Access comprehensive clinical trial information for ChiCTR2200061301 through Pure Global AI's free database. This Phase 1 trial is sponsored by Peking University People's Hospital and is currently Not yet recruiting. The study focuses on Leukemia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Chinese Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
ChiCTR2200061301
Phase 1
Not yet recruiting
Trial Details
Chinese Clinical Trial Registry • ChiCTR2200061301
View on Chinese Clinical Trial Registry
Untitled Trial
A prospective study on the efficacy of tyrosine Kinase Inhibitor combined with chemotherapy in the poorly controlled core binding factor acute myeloid leukemia patients with KIT mutation
Study Focus
Sponsor & Location
Peking University People's Hospital
National Natural Science Foundation of China
China
Timeline & Enrollment
Phase 1
N/A
Aug 01, 2024
ICD-10 Classifications
Leukaemia, unspecified
Myeloid leukaemia
Myeloid leukaemia, unspecified
Other myeloid leukaemia
Monocytic leukaemia, unspecified
Data Source
Chinese Clinical Trial Registry
ChiCTR2200061301
Non-Device Trial